Unlock Premium Data: Up to 50% Off InvestingProCLAIM SALE

Progressive shares price target raised by Cit, rated Neutral

EditorAhmed Abdulazez Abdulkadir
Published 14/06/2024, 19:10
PGR
-

On Friday, Citi updated its stance on Progressive Corp. (NYSE: NYSE:PGR), increasing the insurance company's price target to $232 from $230, while keeping a Neutral rating on the shares. The firm adjusted its expectations following Progressive's May performance, noting the company's solid results despite missing earnings per share (EPS) estimates due to elevated catastrophe losses (CATs).

Progressive reported policy count growth that surpassed expectations, defying the usual seasonal trends. This growth is seen as a positive indicator for the company's ability to maintain strong policy count growth through the typically slower summer months. This outlook aligns with previous comments made by Progressive's CEO on the first quarter earnings call.

The company's higher CATs, particularly in auto insurance, are viewed as a slight negative for Allstate Corp. (NYSE: NYSE:ALL) and The Travelers Companies, Inc. (NYSE: NYSE:TRV). Additionally, Progressive is nearing its attachment point on its homeowners' aggregate treaty, which is expected to provide $85 million of coverage for non-named storm events, potentially boosting EPS in the near future.

Citi has revised its EPS estimates for Progressive for the years 2024 to 2026. The revisions reflect a 4% decrease for 2024 due to the CAT-driven miss in May, but a 2% increase for 2025 and a 1% increase for 2026, primarily due to a stronger investment income run rate. The new price target reflects the updated EPS trajectory for the company.

In other recent news, Progressive Corp reported a significant increase in net income and policy growth in their April earnings report, with net premiums written reaching $6.18 billion and net income for the month standing at $420.3 million. In terms of policy growth, the company saw a 7% increase in personal auto policies and an 8% boost in special lines.

However, Keefe, Bruyette & Woods maintained their Market Perform rating for Progressive with a steady price target of $207.00, adjusting the 2024 earnings per share estimate downward to $11.00 from the previous $11.55.

Meanwhile, Wells Fargo (NYSE:WFC) adjusted its price target for Progressive to $243, a slight decrease from the previous $244 target as the insurance company enters traditionally slower growth months. In contrast, BMO Capital Markets increased the price target on Progressive shares to $235 from the previous target of $234, in light of positive industry developments suggesting a promising future for insurers specializing in personal auto and home coverage.

InvestingPro Insights

Progressive Corp. (NYSE: PGR) continues to make waves in the insurance industry, with a market capitalization of $120.11 billion and a P/E ratio of 20.96, reflecting its significant presence in the market. Analysts have taken note of the company’s performance, with seven analysts revising their earnings upwards for the upcoming period, showcasing confidence in Progressive's financial outlook. This aligns with Citi's recent price target increase and reflects the optimism surrounding the company's future profitability.

InvestingPro data points to a robust revenue growth of nearly 25% over the last twelve months as of Q1 2024, indicating Progressive's ability to expand its financial base in a competitive sector. Moreover, the company’s strong cash flows, which can sufficiently cover interest payments, and a history of maintaining dividend payments for 15 consecutive years, signal a stable financial position that could attract investors seeking consistent returns.

For those interested in deeper analysis, there are additional InvestingPro Tips available for Progressive, including insights on the company's liquidity position and valuation metrics. Subscribers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking further valuable insights into Progressive's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.